THM
THYMIDINE
| Created: | 1999-07-08 |
| Last modified: | 2024-12-02 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 31 |
| Chiral Atom Count | 3 |
| Bond Count | 32 |
| Aromatic Bond Count | 0 |
Chemical Component Summary | |
|---|---|
| Name | THYMIDINE |
| Synonyms | DEOXYTHYMIDINE; 2'-DEOXYTHYMIDINE |
| Systematic Name (OpenEye OEToolkits) | 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione |
| Formula | C10 H14 N2 O5 |
| Molecular Weight | 242.229 |
| Type | DNA OH 5 PRIME TERMINUS |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 10.04 | O=C1NC(=O)N(C=C1C)C2OC(C(O)C2)CO |
| SMILES | CACTVS | 3.341 | CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O |
| SMILES | OpenEye OEToolkits | 1.5.0 | CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O |
| Canonical SMILES | CACTVS | 3.341 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O |
| Canonical SMILES | OpenEye OEToolkits | 1.5.0 | CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O |
| InChI | InChI | 1.03 | InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1 |
| InChIKey | InChI | 1.03 | IQFYYKKMVGJFEH-XLPZGREQSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB04485 |
|---|---|
| Name | Thymidine |
| Groups |
|
| Description | Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.[A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the toxicity of established anti-metabolite chemotherapeutic agents, such as 5-Fluorouracil (FU), Methotrexate (MTX), and Cytosine arabinoside (ara-C).[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent.[A274683, A274688, A274703] |
| Synonyms |
|
| Indication | In combination with [doxecitine], thymidine is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.[L54541] |
| Categories |
|
| CAS number | 50-89-5 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Thymidine kinase 2, mitochondrial | MLLWPLRGWAARALRCFGPGSRGSPASGPGPRRVQRRAWPPDKEQEKEKK... | unknown | substrate |
| Thymidine kinase, cytosolic | MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKC... | unknown | substrate |
| Thymidine phosphorylase | MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLS... | unknown | substrate |
| Solute carrier family 28 member 3 | MELRSTAAPRAEGYSNVGFQNEENFLENENTSGNNSIRSRAVQSREHTNT... | unknown | substrate |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS... | unknown | substrate |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL52609 |
| PubChem | 5789 |
| ChEMBL | CHEMBL52609 |
| ChEBI | CHEBI:17748 |
| CCDC/CSD | THYDIN04, THYDIN06, THYDIN02, THYDIN03, THYDIN05, THYDIN01, THYDIN, THYDIN10, THYDIN09, THYDIN08, THYDIN07 |
| COD | 2104143, 2022066 |














